Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2026 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...
May 11, 2026 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

1Q 2026 Earnings
April 27, 2026 17:15 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

ASGCT 2026 Abstracts
March 30, 2026 16:05 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Lexeo Earnings release
March 03, 2026 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
February 05, 2026 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
January 27, 2026 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Partnership for Cardiac RNA Therapies
January 12, 2026 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
January 08, 2026 07:00 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
December 22, 2025 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference